Credit Suisse’s SELLAS Life Sciences SLS Stock Holding History

Credit Suisse’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13	Closed	-$5K	–	4126
2017 Q4	$5K	Buy	13 +6	+86%	+$2.9K	﹤0.01%	3957
2017 Q3	$4K	Buy	+7	New	+$4.62K	﹤0.01%	4164
2017 Q2	–	Sell	-37	Closed	-$33K	–	3943
2017 Q1	$33K	Buy	+37	New	+$61.3K	﹤0.01%	3759

Other funds holding SLS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Credit Suisse's SLS Position: Q1 2018 in Review

Credit Suisse sold out of SELLAS Life Sciences (SLS) in Q1 2018, closing a stake of 13 shares — an estimated $5K sold.

Credit Suisse first reported a position in SLS in Q1 2017 and held it in 3 quarters. The position peaked at $33K in Q1 2017. 16 funds tracked by Wall St. Rank hold SLS as of Q1 2018.

Credit Suisse reported no remaining SELLAS Life Sciences position as of Q1 2018 after selling out during the quarter.
Credit Suisse sold 13 SELLAS Life Sciences shares in Q1 2018, an estimated $5K.
Credit Suisse first reported a position in SELLAS Life Sciences in Q1 2017 and held it in 3 quarters.
Credit Suisse's SELLAS Life Sciences position peaked at $33K in Q1 2017.
16 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2018.

Based on Credit Suisse's 13F filing for Q1 2018, filed 15 May 2018.